SCHEMBL25362255

SCHEMBL25362255

CC(C)(C)OC(=O)N(Cc1nc(C#N)cs1)C(=O)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.32
RAB9A P51151 3/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
MAPT P10636 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
GRM1 Q13255 1/20 0.32
GPR119 Q8TDV5 3/20 0.31
GBA1 P04062 1/20 0.31
GABRA5 P31644 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31
NPC1 O15118 2/20 0.30
CASP3 P42574 1/20 0.30
SENP8 Q96LD8 1/20 0.30
SENP7 Q9BQF6 1/20 0.30
SENP6 Q9GZR1 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29035424 0.77 GABRA5 (0.33) RAB9AL3MBTL1MAPTCYP1A2CYP2D6
SCHEMBL6339332 0.76 HDAC3 (0.45) L3MBTL1GABRA5KDM4E
SCHEMBL7440479 0.76 MMP1 (0.35) RAB9AL3MBTL1MAPTCYP1A2CYP2D6
SCHEMBL25364182 0.75 GRM2 (0.38) GRM2RAB9AMAPTGBA1ALDH1A1
SCHEMBL23701914 0.74 BCHE (0.33) GRM2GBA1
SCHEMBL25363478 0.73 HDAC1 (0.35) GRM2RAB9AMAPTCYP1A2CYP2C9
SCHEMBL29995697 0.72 GRM2 (0.33) GRM2GPR119
SCHEMBL27218621 0.72 GRM2 (0.33) GRM2GPR119
SCHEMBL6588962 0.72 ALDH1A1 (0.33) ALDH1A1GLA
SCHEMBL5987196 0.72 GRM2 (0.35) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed